PLRZ - Polyrizon Ltd.


13.11
-0.500   -3.814%

Share volume: 23,026
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%

$13.61
-0.50
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
4.85%
1 Month
-1.06%
3 Months
18.64%
6 Months
1,212.18%
1 Year
1,489.09%
2 Year
1,160.58%
Key data
Stock price
$13.11
P/E Ratio 
N/A
DAY RANGE
$13.00 - $14.00
EPS 
N/A
52 WEEK RANGE
$0.00 - $18.20
52 WEEK CHANGE
$1,538.75
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.41
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$36,713
AVERAGE 30 VOLUME 
$45,674
Company detail
CEO: Tomer Izraeli
Region: US
Website: polyrizon-biotech.com
Employees: 0
IPO year: 2024
Issue type:
Market: NASDAQ
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. We are an Israeli corporation, incorporated in January 2005. Our principal executive offices are located at 5 Ha-Tidhar Street, Raanana, 4366507, Israel.

Recent news